Encyclopedia of Medical Immunology

Living Edition
| Editors: Ian MacKay, Noel R. Rose

MALT1 Deficiency

  • Robert P. NelsonJr.Email author
Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-9209-2_105-1



A gene that encodes a protein that augments BCL10-induced activation of NF-kappa B.


In the 1980s, Isaacson et al. suggested that histochemical and genetic similarities exist between Mediterranean lymphoma and primary gastrointestinal lymphoma of follicle center cell origin. These include a dense, noninvasive monotypic lamina propria plasma cell infiltrate, individual gland invasion, clonality, and a common histogenesis from mucosa-associated lymphoid-tissue (MALT) (Isaacson and Wright 1983; Diebold 1988; Horsman et al. 1992). The MALT1gene product is a caspase-like (paracaspase) cysteine protease that participates in the signal transduction cascade triggered by the formation of immunoreceptor/peptide-MHC complexes at T and B cell surfaces. Caspase recruitment domain-containing membrane-associated guanylate kinase protein-1 (CARMA1) mediates T and B cell receptor-induced NF-kappa B...

This is a preview of subscription content, log in to check access.


  1. Bornancin F, Renner F, Touil R, et al. Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation. J Immunol. 2015;194:3723–34.CrossRefGoogle Scholar
  2. Brustle A, Brenner D, Knobbe CB, et al. The NF-kappaB regulator MALT1 determines the encephalitogenic potential of Th17 cells. J Clin Invest. 2012;122:4698–709.CrossRefGoogle Scholar
  3. Diebold J. Malignant lymphoma of mucosa-associated lymphoid tissue. Ann Pathol. 1988;8:340.PubMedGoogle Scholar
  4. Frizinsky S, Rechavi E, Barel O, et al. Novel MALT1 mutation linked to immunodeficiency, immune dysregulation, and an abnormal T cell receptor repertoire. J Clin Immunol. 2019;39:401–13.CrossRefGoogle Scholar
  5. Hachmann J, Salvesen GS. The paracaspase MALT1. Biochimie. 2016;122:324–38.CrossRefGoogle Scholar
  6. Horsman D, Gascoyne R, Klasa R, Coupland R. t(11;18)(q21;q21.1): a recurring translocation in lymphomas of mucosa-associated lymphoid tissue (MALT)? Genes Chromosomes Cancer. 1992;4:183–7.CrossRefGoogle Scholar
  7. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer. 1983;52:1410–6.CrossRefGoogle Scholar
  8. Jabara HH, Ohsumi T, Chou J, et al. A homozygous mucosa-associated lymphoid tissue 1 (MALT1) mutation in a family with combined immunodeficiency. J Allergy Clin Immunol. 2013;132:151–8.CrossRefGoogle Scholar
  9. Lin X, Wang D. The roles of CARMA1, Bcl10, and MALT1 in antigen receptor signaling. Semin Immunol. 2004;16:429–35.CrossRefGoogle Scholar
  10. Mc Guire C, Wieghofer P, Elton L, et al. Paracaspase MALT1 deficiency protects mice from autoimmune-mediated demyelination. J Immunol. 2013;190:2896–903.CrossRefGoogle Scholar
  11. McKinnon ML, Rozmus J, Fung SY, Hirschfeld AF, Del Bel KL, Thomas L, et al. Combined immunodeficiency associated with homozygous MALT1 mutations. J Allergy Clin Immunol. 2014;133(5):1458–62.CrossRefGoogle Scholar
  12. Oeckinghaus A, Wegener E, Welteke V, et al. Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation. EMBO J. 2007;26:4634–45.CrossRefGoogle Scholar
  13. Punwani D, Wang H, Chan AY, Cowan MJ, Mallott J, Sunderam U, et al. Combined immunodeficiency due to MALT1 mutations, treated by hematopoietic cell transplantation. J Clin Immunol. 2015;35(2):135–46.CrossRefGoogle Scholar
  14. Quancard J, Klein T, Fung SY, et al. An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient. Nat Chem Biol. 2019;15(3):304–13.CrossRefGoogle Scholar
  15. Rosenbaum M, Gewies A, Pechloff K, et al. Bcl10-controlled Malt1 paracaspase activity is key for the immune suppressive function of regulatory T cells. Nat Commun. 2019;10:2352.CrossRefGoogle Scholar
  16. Rozmus J, McDonald R, Fung SY, et al. Successful clinical treatment and functional immunological normalization of human MALT1 deficiency following hematopoietic stem cell transplantation. Clin Immunol. 2016;168:1–5.CrossRefGoogle Scholar
  17. Saba NS, Wong DH, Tanios G, et al. MALT1 inhibition is efficacious in both naive and ibrutinib-resistant chronic lymphocytic leukemia. Cancer Res. 2017;77:7038–48.CrossRefGoogle Scholar
  18. Thome M. Multifunctional roles for MALT1 in T-cell activation. Nat Rev Immunol. 2008;8:495–500.CrossRefGoogle Scholar
  19. Tusche MW, Ward LA, Vu F, et al. Differential requirement of MALT1 for BAFF-induced outcomes in B cell subsets. J Exp Med. 2009;206:2671–83.CrossRefGoogle Scholar
  20. Wegener E, Oeckinghaus A, Papadopoulou N, et al. Essential role for IkappaB kinase beta in remodeling Carma1-Bcl10-Malt1 complexes upon T cell activation. Mol Cell. 2006;23:13–23.CrossRefGoogle Scholar
  21. Wiegmann H, Reunert J, Metze D, et al. Refining the dermatological spectrum in primary immunodeficiency: MALT1 deficiency mimicking Netherton- and Omenn syndrome. Br J Dermatol. 2019;  https://doi.org/10.1111/bjd.18091.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Professor of Medicine and PediatricsIndiana University School of Medicine, Immunohematology and TransplantationIndianapolisUSA

Section editors and affiliations

  • M Teresa de la Morena
    • 1
  • R. P. Nelson Jr
    • 2
    • 3
  1. 1.University of Washington and Seattle Children's HospitalSeattleUSA
  2. 2.Professor of Medicine and PediatricsIndiana University School of Medicine Immunohematology and TransplantationIndianapolisUSA
  3. 3.Riley Hospital for Children at Indiana University HealthIndianapolisUSA